Pfizer has successfully completed its offering of 5.85 billion and £1.50 billion of senior unsecured notes.
The notes were offered in a private placement pursuant to Regulation S under the Securities Act of 1993, as amended. Pfizer plans to use the net offering proceeds for general corporate purposes, including funding part of the purchase price of the pending Wyeth acquisition and the refinancing of existing debt.
The notes consist of:
1.85 billion of 3.635% notes due 2013
2.00 billion of 4.75% notes due 2016
2.00 billion of 5.75% notes due 2021
£1.50 billion of 6.50% notes due 2038